Scientists are excitedly investigating retatrutide, a innovative drug from Eli Lilly, as a possible breakthrough in body reduction . Distinct from many existing approaches, retatrutide is a twin-action receptor targeting both GLP-1 and GIP, hormones that impact hunger and blood glucose balance.